Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piotr Rutkowski

Showing results (291-300 of 491) with videos related to

Pageof 50
Sort By:
ESMO Open|August 28, 2020
Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre studyAnastasia Constantinidou, Nicolas Sauve, Silvia Stacchiotti, et al.
Targeted Oncology|March 11, 2023
Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated MelanomaKarolina Piejko, Bożena Cybulska-Stopa, Marcin Ziętek, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 14, 2018
Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trialPiotr Rutkowski, Louie Gaston, Aneta Borkowska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
KIT and PDGFRA mutations and the risk of GI stromal tumor recurrenceHeikki Joensuu, Piotr Rutkowski, Toshirou Nishida, et al.
European Journal of Cancer (Oxford, England : 1990)|February 22, 2026
An updated European organization for research and treatment of cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for merkel cell carcinoma (MCC)Anna Szumera-Ciećkiewicz, Piotr Donizy, Thibault Kervarrec, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2014
Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGISTAgnieszka Wozniak, Piotr Rutkowski, Patrick Schöffski, et al.
The Lancet. Oncology|April 18, 2015
Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trialJean-Yves Blay, Lin Shen, Yoon-Koo Kang, et al.
Journal of Translational Medicine|May 10, 2022
The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021Paolo A Ascierto, Allison Betof Warner, Christian Blank, et al.
The Journal of Dermatological Treatment|May 31, 2021
Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanomaBożena Cybulska-Stopa, Marcin Ziętek, Anna M Czarnecka, et al.
Lancet (London, England)|June 15, 2020
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF<sup>V600</sup> mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trialRalf Gutzmer, Daniil Stroyakovskiy, Helen Gogas, et al.
Pageof 50

Showing results (291-300 of 491) with videos related to

Sort By:
Pageof 50
ESMO Open|August 28, 2020
Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre studyAnastasia Constantinidou, Nicolas Sauve, Silvia Stacchiotti, et al.
Targeted Oncology|March 11, 2023
Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated MelanomaKarolina Piejko, Bożena Cybulska-Stopa, Marcin Ziętek, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 14, 2018
Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trialPiotr Rutkowski, Louie Gaston, Aneta Borkowska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
KIT and PDGFRA mutations and the risk of GI stromal tumor recurrenceHeikki Joensuu, Piotr Rutkowski, Toshirou Nishida, et al.
European Journal of Cancer (Oxford, England : 1990)|February 22, 2026
An updated European organization for research and treatment of cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for merkel cell carcinoma (MCC)Anna Szumera-Ciećkiewicz, Piotr Donizy, Thibault Kervarrec, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2014
Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGISTAgnieszka Wozniak, Piotr Rutkowski, Patrick Schöffski, et al.
The Lancet. Oncology|April 18, 2015
Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trialJean-Yves Blay, Lin Shen, Yoon-Koo Kang, et al.
Journal of Translational Medicine|May 10, 2022
The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021Paolo A Ascierto, Allison Betof Warner, Christian Blank, et al.
The Journal of Dermatological Treatment|May 31, 2021
Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanomaBożena Cybulska-Stopa, Marcin Ziętek, Anna M Czarnecka, et al.
Lancet (London, England)|June 15, 2020
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF<sup>V600</sup> mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trialRalf Gutzmer, Daniil Stroyakovskiy, Helen Gogas, et al.
Pageof 50